Expanding Cell Therapies TC BioPharm is actively developing innovative allogeneic CAR-T and gamma delta T cell therapies for cancer and infectious diseases, presenting opportunities to collaborate on custom cell therapy solutions or supply chain partnerships to support clinical and commercial manufacturing.

Strategic Asset Acquisition Recent asset sales and non-binding acquisition letters indicate a focus on expanding gamma delta T cell platforms and infectious disease treatments, creating potential sales avenues for partnerships, licensing, or supply of specialized cell therapy components.

Funding & Growth Support With recent non-dilutive grants and a significant $8 million capital injection, TC BioPharm demonstrates strong growth momentum, signaling opportunities to provide specialized laboratory equipment, contract manufacturing, or clinical trial services to support their scaling activities.

Technological Innovation The company’s collaboration with Carnegie Mellon University to develop AI solutions for donor screening and matching underscores a willingness to adopt advanced technology, opening doors for sales of AI tools, data management platforms, or software solutions to enhance their R&D and operational efficiencies.

Market & Partner Engagement Participation in investor summits and partnerships with academic experts indicate a proactive approach to investor relations and research collaborations, offering opportunities to engage with stakeholders for investment, joint ventures, or distribution partnerships in emerging cell therapy markets.